Imagotype
Phase 2 Study of Elraglusib (9-Ing-41), a Glycogen Synthase Kinase-3β Inhibitor, in Combination with Gemcitabine Plus Nab-Paclitaxel in Patients with Previously Untreated Metastatic Pancreatic Cancer